TY - JOUR
T1 - BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer
T2 - A Theoretical Proposal
AU - Romo-Perez, Adriana
AU - Dominguez-Gomez, Guadalupe
AU - Chavez-Blanco, Alma
AU - Taja-Chayeb, Lucia
AU - Gonzalez-Fierro, Aurora
AU - García-Martínez, Elisa
AU - Correa-Basurto, Jose
AU - Duenas-Gonzalez, Alfonso
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/10
Y1 - 2022/10
N2 - Cancer therapy advances have yet to impact global cancer mortality. One of the factors limiting mortality burden reduction is the high cost of cancer drugs. Cancer drug repurposing has al-ready failed to meet expectations in terms of drug affordability. The three FDA-approved cancer drugs developed under repurposing: all-trans-retinoic acid, arsenic trioxide, and thalidomide do not differ in price from other drugs developed under the classical model. Though additional factors affect the whole process from inception to commercialization, the repurposing of widely used, com-mercially available, and cheap drugs may help. This work reviews the concept of the malignant metabolic phenotype and its exploitation by simultaneously blocking key metabolic processes altered in cancer. We elaborate on a combination called BAPST, which stands for the following drugs and pathways they inhibit: Benserazide (glycolysis), Apomorphine (glutaminolysis), Panto-prazole (Fatty-acid synthesis), Simvastatin (mevalonate pathway), and Trimetazidine (Fatty-acid oxidation). Their respective primary indications are: • Parkinson's disease (benserazide and apomorphine). • Peptic ulcer disease (pantoprazole). • Hypercholesterolemia (simvastatin). • Ischemic heart disease (trimetazidine). When used for their primary indication, the literature review on each of these drugs shows that they have a good safety profile and lack predicted pharmacokinetic interaction among them. Based on that, we propose that the BAPST regimen merits preclinical testing.
AB - Cancer therapy advances have yet to impact global cancer mortality. One of the factors limiting mortality burden reduction is the high cost of cancer drugs. Cancer drug repurposing has al-ready failed to meet expectations in terms of drug affordability. The three FDA-approved cancer drugs developed under repurposing: all-trans-retinoic acid, arsenic trioxide, and thalidomide do not differ in price from other drugs developed under the classical model. Though additional factors affect the whole process from inception to commercialization, the repurposing of widely used, com-mercially available, and cheap drugs may help. This work reviews the concept of the malignant metabolic phenotype and its exploitation by simultaneously blocking key metabolic processes altered in cancer. We elaborate on a combination called BAPST, which stands for the following drugs and pathways they inhibit: Benserazide (glycolysis), Apomorphine (glutaminolysis), Panto-prazole (Fatty-acid synthesis), Simvastatin (mevalonate pathway), and Trimetazidine (Fatty-acid oxidation). Their respective primary indications are: • Parkinson's disease (benserazide and apomorphine). • Peptic ulcer disease (pantoprazole). • Hypercholesterolemia (simvastatin). • Ischemic heart disease (trimetazidine). When used for their primary indication, the literature review on each of these drugs shows that they have a good safety profile and lack predicted pharmacokinetic interaction among them. Based on that, we propose that the BAPST regimen merits preclinical testing.
KW - Cancer drug repurposing
KW - de novo fatty-acid synthesis
KW - fatty-acid oxidation
KW - glutaminolysis
KW - glycolysis
KW - mevalonate pathway
UR - http://www.scopus.com/inward/record.url?scp=85134632200&partnerID=8YFLogxK
U2 - 10.2174/1874467214666211006123728
DO - 10.2174/1874467214666211006123728
M3 - Estudio breve
C2 - 34620071
AN - SCOPUS:85134632200
SN - 1874-4672
VL - 15
SP - 815
EP - 831
JO - Current Molecular Pharmacology
JF - Current Molecular Pharmacology
IS - 6
ER -